

ing the full immunisation coverage and ensuring that the benefit of the life-saving vaccines is provided to every child. According to the National Family Health Survey 2015-16, the immunisation coverage in India stood at 62 per cent, lagging behind China (90 per cent), Bangladesh (95 per cent) and Sri Lanka (95 per cent).

Three doses of rotavirus vaccine are provided along with other vaccines, free of cost, under Universal Immunisation Programme at one-and-a-half-month, two-and-half-month, and three-and-half-month of age.

ERING LIMITED

minations Limited]
1983PLC004141
r, Padmaja Landmark, Somajiguda,
www.pitti.in, Ph: 040-23312774,
Email : shares@pitti.in,

IAL RESULTS FOR THE JUNE, 2019 (₹. IN LAKHS)

QUARTER ENDED 0-06-2019 Un-Audited	YEAR ENDED 31-03-2019 Audited	QUARTER ENDED 30-06-2018 Un-Audited
5,021.46	62,448.14	13,098.33
712.40	4,033.81	680.35
712.40	4,033.81	680.35
449.00	2,371.96	403.37
451.81	2,286.89	414.95
1,602.92	1,491.81	1,491.81
-	15,604.58	-
1.50	7.67	1.39
1.50	7.14	1.29

ed by the Audit Committee on 9th
irectors at their meeting held on 9th

is adopted IND AS-116. The Company
ing equivalent right-of-use assets. In
quarter, operating lease expenses
vious periods is now recognised as
s and finance cost for interest accrued
6 did not have any significant impact

regrouped and reclassified wherever
resentation.

of the financial results for the Quarter
ange under Regulation 33 of the SEBI
ts) Regulations, 2015. The full format
June 2019 are available on www.pitti.in,

For Pitti Engineering Limited
Sd/-
(SHARAD B PITTI)
Chairman & Managing Director
DIN: 00078716

been busier," said Kogelo
Caceres, co-founder and CCO of
LCR Capital Partners, An EB-5
Regional Center.

"We anticipate an increase of
300 per cent in the number of
new Indian EB-5 investors over

investors seeking to apply
under the old rules until
November 21. This will lead to
delays in processing and those
applying after November 21
may face a significantly longer
waiting period."

ments name, primarily as a bulk
of EB-5 demand comes from In-
dians already residing in the
US.

The writer is an intern with
BusinessLine

Bokaro Power Supply Co. (P) Ltd.

(A Joint Venture of SAIL & DVC)
Hall No. : M-01, Old Administrative Building
Ispat Bhavan, Bokaro Steel City-827001(Jharkhand)
CIN No. : U40300DL2001PTC112074

NOTICE INVITING TENDER

Ref. No. : BPSCL/P&C/19-20/Paper Advt./2823 Dated : 09.08.2019

Sl.No.	NIT No. / Date	Description	BOD & Time
01.	BPSCL/P&C/19-20/PUR-076/ NIT-819/2793 dt.07.08.2019	Procurement of Sulphuric Acid (Commercial Grade) 98%	10.09.2019 at 12.15 Hrs.
02.	BPSCL/P&C/19-20/PUR-088/ NIT-820/2791 dt.07.08.2019	Procurement of Tri-Sodium Phosphate Technical Grade (Dodecahydrate)	10.09.2019 at 12.15 Hrs.
03.	BPSCL/P&C/19-20/C-070/ NIT-821/2788 dt.07.08.2019	Assistance in Electrical Operation of Boiler, Turbine, Generator & Associated Auxiliaries of Unit #9	06.09.2019 at 12.15 Hrs.
04.	BPSCL/P&C/19-20/PUR-089/ NIT-822/2792 dt.07.08.2019	Procurement of materials for Railway Track Maintenance	10.09.2019 at 12.15 Hrs.
05.	BPSCL/P&C/19-20/C-072/ NIT-823/2809 dt.08.08.2019	Replacement of furnace oil lines from Boiler # 8 to Boiler # 5 including their branch lines to CPP Boilers # 6, 7 & 8	06.09.2019 at 12.15 Hrs.

For Tender documents kindly visit Website : www.bpscl.com, Bidders are requested to visit website regularly.

NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
Phone:040-23547532, Email : investors@natcopharma.co.in
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Consolidated Unaudited Financial Results for the quarter ended June 30, 2019

All amounts in Indian Rupees millions except share data

Sl. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Revenue from operations	4,923	4,557	5,386	20,945
2	Net Profit for the period (before Tax, Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
3	Net Profit for the period before tax (after Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
4	Net Profit for the period after tax (after exceptional and /or Extraordinary items) and non-controlling interests	1,432	1,208	1,816	6,444
5	Total Comprehensive Income for the period attributable to owners of the parent	1,449	1,174	1,829	6,368
6	Equity share capital	364	365	369	365
7	Other Equity	-	-	-	34,525
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)				
	a) Basic	7.87	6.59	9.84	34.98
	b) Diluted	7.85	6.58	9.82	34.87

Notes:
1. Summarized Unaudited Standalone Financial Results of the Company is as under : All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Income from operations	4,647	4,163	5,157	19,863
2	Net Profit for the period before tax	1,883	1,544	2,398	8,474
3	Net Profit for the period after tax	1,477	1,234	1,886	6,671

2 "The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."

3 The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on August 09, 2019.

4 "The Board of Directors at their meeting held on August 09, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each."

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

Businessline ... Hyderabad 10/8/19

	for the period (after tax) and other Comprehensive Income (after tax)	539.03	539.03	539.03	539.03
6	Equity share capital				4,727.87
7	Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of previous year)				
8	Earnings Per Share (Face Value Rs. 1/- each)	0.54	0.54	0.69	2.18
	Basic:	0.54	0.54	0.69	2.18
	Diluted:				

Notes :

- The above is an extract of the detailed format of Quarterly financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results are available on the Stock Exchange website www.bseindia.com and the website of the Company www.ovpl.co.in
- The above financial results have been reviewed by the Audit Committee & approved by the Board of Directors in its meeting held on August 08, 2019. The Statutory Auditors have carried out a Limited Review of the above financial results. The unaudited consolidated financial result for quarter ended June 30, 2018, was not subject to limited review report by Statutory Auditor of the Company.
- The Earnings per share information in the financial results reflect the effect of sub-division for each of the periods presented.

For **Oriental Veneer Products Limited**
sd/-
Karim N. Mithiborwala
Managing Director

Date : August 08, 2019
Place : Mumbai

Rameshwar Media



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
Phone:040-23547532, Email : investors@natcopharma.co.in
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Consolidated Unaudited Financial Results for the quarter ended June 30, 2019

All amounts in Indian Rupees millions except share data

Sl. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Revenue from operations	4,923	4,557	5,386	8,247
2	Net Profit for the period (before Tax, Exceptional and /or Extraordinary Items)	1,838	1,524	2,323	8,247
3	Net Profit for the period before tax (after Exceptional and /or Extraordinary items)	1,432	1,208	1,816	6,444
4	Net Profit for the period after tax (after exceptional and /or Extraordinary items) and non-controlling interests	1,449	1,174	1,829	6,368
5	Total Comprehensive Income for the period attributable to owners of the parent	364	365	369	365
6	Equity share capital	-	-	-	34,525
7	Other Equity	-	-	-	-
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)	7.87	6.59	9.84	34.98
	a) Basic	7.85	6.58	9.82	34.87
	b) Diluted				

Notes:
1. Summarized Unaudited Standalone Financial Results of the Company is as under : All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Income from operations	4,647	4,163	5,157	19,863
2	Net Profit for the period before tax	1,883	1,544	2,398	8,474
3	Net Profit for the period after tax	1,477	1,234	1,886	6,671

2 "The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."

3 The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on August 09, 2019.

4 "The Board of Directors at their meeting held on August 09, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each"

for **NATCO Pharma Limited**

il.com
RTER
stated)
ended
3.2019
dited
17.33
4.23
3.13
3.13
31.02
-
0.025
0.025

2019 filed
ions, 2015,
available on

ctors at their
the quarter
half of
ces Ltd
ani

LTD.
5PLC007868
TIME 2019



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
Phone:040-23547532, Email : investors@natcopharma.co.in
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Consolidated Unaudited Financial Results for the quarter ended June 30, 2019

All amounts in Indian Rupees millions except share data

Sl. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Revenue from operations	4,923	4,557	5,386	20,945
2	Net Profit for the period (before Tax, Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
3	Net Profit for the period before tax (after Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
4	Net Profit for the period after tax (after exceptional and /or Extraordinary items) and non-controlling interests	1,432	1,208	1,816	6,444
5	Total Comprehensive Income for the period attributable to owners of the parent	1,449	1,174	1,829	6,368
6	Equity share capital	364	365	369	365
7	Other Equity	-	-	-	34,525
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)				
	a) Basic	7.87	6.59	9.84	34.98
	b) Diluted	7.85	6.58	9.82	34.87

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under : All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Income from operations	4,647	4,163	5,157	19,863
2	Net Profit for the period before tax	1,883	1,544	2,398	8,474
3	Net Profit for the period after tax	1,477	1,234	1,886	6,671

2 "The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."

3 The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on August 09, 2019.

4 "The Board of Directors at their meeting held on August 09, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each."

Place: Hyderabad
Date: 9 August 2019

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

Camlin

KOKUYO CAMLIN LIMITED

9. Electronic Voting Event Number (EVEN)
- h. The Notice of EOGM is available at <https://www.persistent.com/investors> also on the website of NSDL at <https://www.evoting.nsdl.com>
- i. Any person, who acquires shares of the Company after dispatch of the notice a i.e. Wednesday, August 28, 2019, may send a request at evoting@nsdl.com. However, if a member is already registered he/she can use their existing Login ID. Member forgot his/her password, he/she can use "Forgot User Details/Password?" or "New User" available on www.evoting.nsdl.com or call on no.: 1800-222-990 or Members may also send a request at evoting@nsdl.com
- j. For electronic voting instructions and instructions Members may go through the instructions Frequently Asked Questions (FAQs) and download section of www.evoting.nsdl.com or send a request at evoting@nsdl.com
- k. For any queries / grievances in relation to Mr. Ashok Sherugar, AVP-Corporate Affairs, Limited, C-101, 247 Park, L.B.S. Marg, Hyderabad. No.: +91 (22) 49186000, e-mail ID: ashok@natcopharma.com
- l. The above mentioned details are also available on the Company's website: <https://www.persistent.com/investors>
- Company's website: <https://www.persistent.com/investors>
 - NSDL: <https://www.evoting.nsdl.com>
 - BSE Limited: www.bseindia.com
 - National Stock Exchange of India Limited: www.nseindia.com

Place : Pune
Date : August 9, 2019

పంపిణీ 2019,
 వరకు
 లల
 గలకు
 పాధ్యాయులే
 గా నిధులు
 వేశారని
 గారు. దీంతో
 పెట్టిన
 క్షమ
 త్రంతో
 చేసుకునేం
 అవకాశం
 వాలని
 విత్తా
 తి ఉన్న
 ను రద్దు
 లని
 వారు.

ED
 gana.
 ers.com
 in Lakhs)
 2019
 nded
 ar-19
 lited
 3.51
 8.78)
 8.78)
 1.77)
 12.55)
 4.39
 5.45
 80)
 bay Stock
 rat of the
 ompany's
 s meeting
 ter Ended
 LIMITED
 A.J GOEL
 IRECTOR

సంపాదించిన రాబడి (రూ.4/-వేలకు)					
అందులో:					
ఫీస్	1.02	0.10	(0.78)	0.26	(2.52)
ప్రొఫిట్	1.00	0.09	(0.74)	0.25	(2.41)

గమనిక: సబ్ (బస్) అండ్ అదర్ ట్రైబ్యూనల్స్, 2015 యొక్క రెగ్యులేషన్ 33 క్రింద స్టాక్ ఎక్స్చేంజ్లో దాఖలయ్యే అనుబంధిత ట్రాన్సాక్షన్లకు అర్హత
 ఫలితాల యొక్క వివరణాత్మక ఫార్మ్ (ASX) యొక్క సారాంశంపై వివరాలు ఉన్నాయి. ట్రాన్సాక్షన్లకు అర్హత ఫలితాల పూర్తి వివరాల స్టాక్ ఎక్స్చేంజ్లో వెబ్సైట్లో
 ఎంటర్ చేసి అందుబాటులో ఉండే ట్రాన్సాక్షన్లపై యొక్క యాజమాన్యం: www.olectra.com, www.bseindia.com, www.nseindia.com
 For Olectra Greentech Limited
 ఎస్.వి.నానపాణి
 మేనేజింగ్ డైరెక్టర్
 DIN: 01630545

ప్రదేశం: సికింద్రాబాద్
 తేదీ: 09-08-2019



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
 Phone:040-23547532, Email : investors@natcopharma.co.in
 CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Consolidated Unaudited Financial Results for the quarter ended June 30, 2019

All amounts in Indian Rupees millions except share data

Sl. No.	Particulars	Consolidated			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Revenue from operations	4,923	4,557	5,386	20,945
2	Net Profit for the period (before Tax, Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
3	Net Profit for the period before tax (after Exceptional and /or Extraordinary items)	1,838	1,524	2,323	8,247
4	Net Profit for the period after tax (after exceptional and /or Extraordinary items and non-controlling interests)	1,432	1,208	1,816	6,444
5	Total Comprehensive Income for the period attributable to owners of the parent	1,449	1,174	1,829	6,368
6	Equity share capital	364	365	369	365
7	Other Equity	-	-	-	34,525
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)				
	a) Basic	7.87	6.59	9.84	34.98
	b) Diluted	7.85	6.58	9.82	34.87

Notes:
 1. Summarized Unaudited Standalone Financial Results of the Company is as under: All amounts in Indian Rupees millions

Sl. No.	Particulars	Standalone			
		Quarter ended			Year ended
		30/06/2019 (Unaudited)	31/03/2019 (Audited)	30/06/2018 (Unaudited)	31/03/2019 (Audited)
1	Total Income from operations	4,647	4,163	5,157	19,863
2	Net Profit for the period before tax	1,883	1,544	2,398	8,474
3	Net Profit for the period after tax	1,477	1,234	1,886	6,671

- "The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange(s) websites: www.nseindia.com and www.bseindia.com and on the Company's website www.natcopharma.co.in."
- The above financial results have been reviewed by the Audit Committee of the board and approved by the Board of Directors at their respective meetings held on August 09, 2019.
- "The Board of Directors at their meeting held on August 09, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each."

Place: Hyderabad
 Date: 9 August 2019
 for NATCO Pharma Limited
 Sd/- V.C. Nannapaneni
 Chairman & Managing Director

10/8/19

Nava Telangana Hyd